In recent years, the therapeutic potential of synthetic peptides has garnered significant attention, particularly in the realms of neurology and psychiatry. Among these peptides, Semax and Selank stand out due to their unique neuroprotective properties and promising applications for cognitive enhancement and stress modulation. Originally developed in Russia for the treatment of neurological disorders, these peptides have since attracted global interest for their nootropic and anxiolytic effects. This article aims to provide a comprehensive overview of Semax and Selank, exploring their molecular mechanisms, clinical applications, and current research insights relevant to scientists and clinicians.
Semax is a synthetic heptapeptide analog derived from the adrenocorticotropic hormone (ACTH) fragment 4-10 with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design enables it to resist enzymatic degradation, thereby extending its biological activity in the central nervous system (CNS). Selank is a synthetic heptapeptide analog of the endogenous tetrapeptide tuftsin, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Like Semax, it exhibits resistance to proteolytic enzymes, ensuring prolonged efficacy.
Both peptides are administered intranasally, allowing for rapid CNS penetration by bypassing the blood-brain barrier through the olfactory and trigeminal nerve pathways. This mode of delivery enhances bioavailability and reduces systemic side effects commonly associated with oral or intravenous administration.
Semax
Semax exhibits multifaceted neuroprotective and neuromodulatory effects. It modulates the expression of brain-derived neurotrophic factor (BDNF), a critical neurotrophin involved in synaptic plasticity, learning, and memory. By upregulating BDNF mRNA and protein levels in the hippocampus and cerebral cortex, Semax enhances neurogenesis and synaptic remodeling, processes essential for cognitive enhancement.
Furthermore, Semax modulates the activity of monoamine neurotransmitters including dopamine, serotonin, and norepinephrine. It exerts antioxidant effects, reducing oxidative stress-induced neuronal damage, and facilitates the restoration of cerebral blood flow in ischemic conditions. Semax also exhibits anti-inflammatory properties by downregulating pro-inflammatory cytokines such as TNF-α and IL-6.
Selank
Selank’s anxiolytic and cognitive-enhancing effects are primarily attributed to its modulation of the GABAergic and serotonergic systems. Selank increases the expression of enkephalins, endogenous opioid peptides involved in pain modulation and emotional regulation. Its interaction with GABA_A receptors contributes to anxiolysis without sedation, contrasting with benzodiazepines.
Selank also influences the expression of BDNF and modulates the balance of pro- and anti-inflammatory cytokines, thereby exerting immunomodulatory effects. Notably, Selank has been shown to regulate the hypothalamic-pituitary-adrenal (HPA) axis, normalizing cortisol levels in stress conditions, which is crucial for adaptive stress responses.
Cognitive Enhancement
Both peptides demonstrate significant potential in improving cognitive functions such as attention, memory, and learning. Semax has been extensively studied in patients with ischemic stroke, traumatic brain injury, and cognitive impairments, where it enhances recovery and neural plasticity. Clinical trials report improved verbal memory, executive function, and psychomotor speed after Semax treatment.
Selank, while primarily recognized for its anxiolytic properties, also improves cognitive flexibility and working memory. Studies involving healthy volunteers reveal enhanced attention span and reduced mental fatigue with Selank administration. Its ability to mitigate anxiety-induced cognitive impairment further supports its role in cognitive enhancement.
Stress-related disorders and anxiety are prevalent in modern society, underscoring the need for novel treatments. Selank has demonstrated efficacy comparable to classical anxiolytics, but without adverse effects such as tolerance or dependence. Clinical studies indicate that Selank reduces anxiety scores in generalized anxiety disorder and improves mood in depressive states.
Semax indirectly contributes to stress modulation through neuroprotection and normalization of neurotransmitter systems affected by chronic stress. By reducing oxidative stress and inflammation, Semax supports resilience to stress-induced neuronal damage.
The neuroprotective properties of Semax and Selank extend their applications to neurorehabilitation. Both peptides have been investigated in ischemic stroke, where they promote neuronal survival and functional recovery. Semax, in particular, is approved in Russia for stroke rehabilitation, improving neurological outcomes and reducing infarct size.
Selank’s immunomodulatory effects contribute to neuroprotection by preventing excessive inflammatory responses that exacerbate brain injury. These peptides offer promising adjunctive therapies to conventional neurorehabilitation protocols.
Clinical trials and post-marketing surveillance report excellent safety profiles for Semax and Selank. Due to their peptide nature and targeted CNS delivery, systemic side effects are minimal. No significant toxicity, habituation, or withdrawal phenomena have been observed, making them favorable options for long-term use in chronic neurological and psychiatric conditions.
Despite encouraging data, further research is warranted to elucidate the full therapeutic potential and molecular targets of Semax and Selank. Areas of active investigation include their roles in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, where modulation of neurotrophic factors and inflammation are critical.
Pharmacokinetic and pharmacodynamic studies are needed to optimize dosing regimens, particularly in diverse populations. Moreover, comparative studies against established pharmacotherapies will clarify their place in clinical practice.
The integration of advanced imaging techniques and biomarker analyses will deepen understanding of their CNS effects and facilitate personalized medicine approaches.
Semax and Selank represent a novel class of neuropeptides with distinct and complementary mechanisms supporting cognitive enhancement and stress modulation. Their multifactorial actions on neurotrophic support, neurotransmitter balance, oxidative stress, and immune regulation underscore their therapeutic versatility. With robust safety profiles and growing clinical evidence, these peptides hold promise as innovative interventions in neurology and psychiatry.
Ashmarin IP, et al. Semax: a review of experimental and clinical data. Neuroscience and Behavioral Physiology, 2007; 37(8): 857-869.
Myasoedova VA, et al. Selank as a novel anxiolytic peptide: preclinical and clinical data. Current Pharmaceutical Design, 2018; 24(33): 3837-3846.
Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders worldwide, characterized by progressive cognitive decline and memory impairment. Despite decades of research, therapeutic
Aging is a multifaceted biological process characterized by a progressive decline in physiological function and increased vulnerability to chronic diseases. At the cellular level, one
Aging is an intricate biological process characterized by the gradual decline in cellular and systemic functions, ultimately leading to increased susceptibility to diseases and mortality.
Mitochondrial-derived peptides (MDPs) have recently attracted significant interest for their multifaceted roles in cellular homeostasis, metabolism, and aging. Among these, MOTS-c (Mitochondrial Open Reading Frame
Copper peptides have long captured the attention of dermatologists and cosmetic chemists for their remarkable regenerative properties. Among them, GHK-Cu (glycyl-L-histidyl-L-lysine–copper) has emerged as a
